Found: 2
Select item for more details and to access through your institution.
Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors.
- Published in:
- Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 445, doi. 10.1007/s00262-017-2095-7
- By:
- Publication type:
- Article
P21-Activated Kinase 1 (PAK1) as a Therapeutic Target in BRAF Wild-Type Melanoma.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2013, v. 105, n. 9, p. 606, doi. 10.1093/jnci/djt054
- By:
- Publication type:
- Article